TNC vs TTNP vs NDSN vs NKTR vs ITW

For growth investors, Nordson Corporation (NDSN) is the stronger pick with 3.

8% revenue growth year-over-year, versus -100. 0% for Titan Pharmaceuticals, Inc. (TTNP). Illinois Tool Works Inc. (ITW) offers the better valuation at 24. 4x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Tennant Company (TNC) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Illinois Tool Works Inc.

(ITW) is the cheapest at 24. 4x versus Tennant Company at 36. 9x. On forward P/E, Tennant Company is actually cheaper at 17. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Nordson Corporation wins at 1. 68x versus Tennant Company's 3. 20x — a reasonable growth-adjusted valuation.

Over the past 5 years, Nordson Corporation (NDSN) delivered a total return of +42.

4%, compared to -93. 4% for Titan Pharmaceuticals, Inc. (TTNP). Over 10 years, the gap is even starker: NDSN returned +297. 4% versus TTNP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illinois Tool Works Inc.

(ITW) is the lower-risk stock at 0. 68β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 171% more volatile than ITW relative to the S&P 500. On balance sheet safety, Tennant Company (TNC) carries a lower debt/equity ratio of 57% versus 3% for Illinois Tool Works Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nordson Corporation (NDSN) is pulling ahead at 3.

8% versus -100. 0% for Titan Pharmaceuticals, Inc. (TTNP). On earnings-per-share growth, the picture is similar: Titan Pharmaceuticals, Inc. grew EPS 29. 4% year-over-year, compared to -46. 1% for Tennant Company. Over a 3-year CAGR, TNC leads at 3. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illinois Tool Works Inc.

(ITW) is the more profitable company, earning 19. 1% net margin versus -280. 5% for Titan Pharmaceuticals, Inc. — meaning it keeps 19. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITW leads at 26. 3% versus -261. 1% for TTNP. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Nordson Corporation (NDSN) is the more undervalued stock at a PEG of 1. 68x versus Tennant Company's 3. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Tennant Company (TNC) trades at 17. 4x forward P/E versus 24. 8x for Nordson Corporation — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TNC: 60. 9% to $140. 00.

In this comparison, ITW (2.

4% yield), TNC (1. 4% yield), NDSN (1. 1% yield) pay a dividend. TTNP, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Illinois Tool Works Inc.

(ITW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68), 2. 4% yield, +188. 6% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ITW: +188. 6%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TNC (Industrials) and TTNP (Healthcare) and NDSN (Industrials) and NKTR (Healthcare) and ITW (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

TNC, NDSN, ITW pay a dividend while TTNP, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.